Valuation: Autolus Therapeutics plc

Market Cap 610M 526M 495M 450M 847M 58.4B 859M 5.81B 2.28B 29.21B 2.29B 2.24B 97.29B P/E 2026 *
-2.97x
P/E 2027 * -3.39x
Enterprise Value 553M 477M 449M 408M 768M 52.94B 779M 5.27B 2.06B 26.48B 2.07B 2.03B 88.19B EV / Sales 2026 *
3.69x
EV / Sales 2027 * 3.53x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day+0.44%
1 week-1.72%
Current month+53.69%
1 month+59.03%
3 months+27.22%
6 months+46.79%
Current year+15.08%
1 week 2.04
Extreme 2.04
2.34
1 month 1.38
Extreme 1.38
2.43
Current year 1.18
Extreme 1.175
2.43
1 year 1.18
Extreme 1.175
2.43
3 years 1.1
Extreme 1.105
7.45
5 years 1.1
Extreme 1.105
7.9
10 years 1.1
Extreme 1.105
53.24
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 01/09/2014
Chief Executive Officer 61 01/03/2016
Director of Finance/CFO 56 07/08/2023
Director TitleAgeSince
Chairman 61 01/10/2014
Director/Board Member 78 01/08/2014
Director/Board Member 71 01/03/2018
Date Insider Type Main position Quantity % Market Cap.
29/6/26 Free

Director

79,167 0.0477%
18/3/26 Other

General Counsel

780,818 0.4700%
18/3/26 Other

Controller/Auditor

331,000 0.1992%
Change 5-day change 1-year change 3-year change Capi.($)
+0.44%-1.72%+21.81%-27.30% 610M
+0.53%+1.66%+41.18%-0.27% 80.91B
-1.10%-4.85%-3.14%+29.15% 50.13B
+0.05%-2.07%+12.83%+166.50% 47.97B
+5.49%+20.25%-26.17%-37.62% 53.62B
+1.63%+4.25%+56.39%-18.61% 31.41B
-2.33%+3.95%+124.14%-38.04% 25.14B
-0.02%+1.98%+45.40%+92.80% 25.03B
+1.66%+2.83%+0.51%+215.41% 21.45B
+0.60%+5.08%+67.29%+127.78% 16.93B
Average +10.14%+2.18%+34.02%+50.98% 35.32B
Weighted average by Cap. +7.61%+2.42%+27.12%+42.35%

Financials

2026 *2027 *
Net sales 150M 129M 122M 111M 208M 14.35B 211M 1.43B 560M 7.18B 562M 550M 23.91B 192M 166M 156M 142M 267M 18.44B 271M 1.83B 719M 9.22B 722M 707M 30.71B
Net income -212M -183M -173M -157M -295M -20.34B -299M -2.02B -793M -10.17B -797M -780M -33.89B -184M -159M -149M -136M -255M -17.6B -259M -1.75B -686M -8.8B -690M -675M -29.33B
Net Debt -57M -49.23M -46.32M -42.1M -79.18M -5.46B -80.34M -543M -213M -2.73B -214M -209M -9.1B 69.6M 60.11M 56.56M 51.4M 96.68M 6.67B 98.1M 663M 260M 3.34B 261M 256M 11.11B
Logo Autolus Therapeutics plc
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Employees
753
Date Price Change Volume
18/08/26 USD 2.290 +0.44% 3,363,410
17/08/26 USD 2.280 +6.05% 3,036,041
14/08/26 USD 2.150 -3.15% 2,395,470
13/08/26 USD 2.220 +4.72% 2,242,456
12/08/26 USD 2.120 -9.01% 4,059,386
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
2.290USD
Average target price
8.725USD
Spread / Average Target
+281.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AUTL Stock